We Just Had An Epiphany
Tag: featured-epiphany
🌊 The $2 Trillion ETF Tsunami: How to Invest When the Market Looks Expensive 🛡️
ETFs have transformed investing.
They're cheaper.
Smarter.
More diversified.
But one question remains:
Can the world's greatest investment vehicle still produce disappointing returns if the assets inside it are expensive?
With Goldman Sachs forecasting more than $2 trillion of ETF inflows while the S&P 500 trades at roughly twice its historical average valuation, disciplined portfolio construction has rarely mattered more.
📹 Zoom (ZM): Wall Street Still Thinks It's a Video Company. What If It's Becoming an AI Platform? 🤖
Wall Street still sees Zoom as a pandemic-era video conferencing company.
We think that narrative is becoming outdated.
With a fortress balance sheet, nearly $1.7 billion in annual free cash flow, AI Companion, Zoom Phone, Contact Center and Workvivo, Zoom may quietly be evolving into a broader enterprise communications platform.
🧬 Moderna (NASDAQ: MRNA) Stock Analysis: Why We Still Believe This mRNA Pioneer Is Undervalued
Moderna has already doubled from its 2025 lows, yet we believe the story is still in its early chapters. Science Day confirmed that Moderna is becoming far more than a vaccine company—it's building one of biotechnology's most ambitious programmable medicine platforms.
🦸♂️ The Attic of the Soul: Why Your $9M “Super Moment” Is Covered in Dust
A dusty attic revealed a $9.1M treasure. Most of us have something similar—buried ideas, talents, or ambitions waiting to be rediscovered. The question is: will you climb the ladder?
S&P 500 PE Ratio Hits 30: Is a 2026 Bear Market Black Swan Immersion Imminent?
With the S&P 500 trading at nearly twice its historical P/E average, valuations are stretched. Even a 20% drop wouldn’t make stocks cheap. Is 2026 the year gravity reasserts itself?
No Bullish Trigger: Ginkgo Bioworks Should Read “Ginkgo Bio… Doesn’t Work”
Ginkgo Bioworks (DNA) has ambitious science and flashy AI rhetoric — but declining revenues, deep losses, and no insider conviction make this a tough stock to love. 🧬📉
Match Group (MTCH) Update: CEO Keeps Swiping Buy + Hinge Still Crushing It
Spencer Rascoff is swiping right on Match Group. With Hinge outpacing Tinder, free cash flow flowing, and big-name funds saying “I do,” is this the rebound stock your portfolio’s been hoping for?